About Us > Overview
ProtAffin AG is a European biotechnology company that has developed a new technology for generating biopharmaceuticals addressing many of the highest priority disease targets in the pharmaceutical industry. ProtAffin’s proprietary CellJammer® discovery technology allows for the development of biopharmaceuticals that bind glycans. ProtAffin has applied this technology to generate drug candidates in the fields of inflammation, respiratory and oncology.
The company has 25 employees located in Graz, Austria and in London, UK. The Company also has a leading global network of advisors that will support the long-term commercial success of the business.
